These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 37005546)

  • 21. Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications.
    Hydes T; Brown E; Hamid A; Bateman AC; Cuthbertson DJ
    Clin Ther; 2021 Sep; 43(9):1505-1522. PubMed ID: 34400007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Research advances in diagnosis of non-alcoholic fatty liver disease].
    Wang JH; Yu CH
    Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):115-118. PubMed ID: 28297797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
    Zhou JH; Cai JJ; She ZG; Li HL
    World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma.
    Lewinska M; Santos-Laso A; Arretxe E; Alonso C; Zhuravleva E; Jimenez-Agüero R; Eizaguirre E; Pareja MJ; Romero-Gómez M; Arrese M; Suppli MP; Knop FK; Oversoe SK; Villadsen GE; Decaens T; Carrilho FJ; de Oliveira CP; Sangro B; Macias RIR; Banales JM; Andersen JB
    EBioMedicine; 2021 Nov; 73():103661. PubMed ID: 34740106
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MicroRNA signature in patients with hepatocellular carcinoma associated with type 2 diabetes.
    Elemeery MN; Mohamed MA; Madkour MA; Shamseya MM; Issa NM; Badr AN; Ghareeb DA; Pan CH
    World J Gastroenterol; 2019 Nov; 25(42):6322-6341. PubMed ID: 31754293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease.
    Beale G; Chattopadhyay D; Gray J; Stewart S; Hudson M; Day C; Trerotoli P; Giannelli G; Manas D; Reeves H
    BMC Cancer; 2008 Jul; 8():200. PubMed ID: 18638391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease.
    Seif El Dahan K; Daher D; Singal AG
    Clin Mol Hepatol; 2023 Feb; 29(Suppl):S207-S219. PubMed ID: 36103899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and Validation of a Novel Circulating miRNA-Based Diagnostic Score for Early Detection of Hepatocellular Carcinoma.
    Yu B; Zhou S; Liang H; Ye Q; Wang Y
    Dig Dis Sci; 2022 Jun; 67(6):2283-2292. PubMed ID: 33982217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.
    Mohamad B; Shah V; Onyshchenko M; Elshamy M; Aucejo F; Lopez R; Hanouneh IA; Alhaddad R; Alkhouri N
    Hepatol Int; 2016 Jul; 10(4):632-9. PubMed ID: 26558795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis.
    Dongiovanni P; Meroni M; Longo M; Fargion S; Fracanzani AL
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting Non-Alcoholic Fatty Liver Disease Progression and Immune Deregulations by Specific Gene Expression Patterns.
    Zeng F; Zhang Y; Han X; Zeng M; Gao Y; Weng J
    Front Immunol; 2020; 11():609900. PubMed ID: 33574818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct Morphological and Molecular Profiles of NAFLD and NAFLD-associated HCC Revealed by Immunohistochemistry and MicroRNA Analysis.
    Rusu I; Pirlog R; Chiroi P; Nutu A; Budisan L; Puia VR; Braicu C; Berindan-Neagoe I; Al Hajjar N
    J Gastrointestin Liver Dis; 2023 Sep; 32(3):356-366. PubMed ID: 37494555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis.
    Tovo CV; de Mattos AZ; Coral GP; Sartori GDP; Nogueira LV; Both GT; Villela-Nogueira CA; de Mattos AA
    World J Gastroenterol; 2023 Jan; 29(2):343-356. PubMed ID: 36687125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population.
    Liu XL; Pan Q; Zhang RN; Shen F; Yan SY; Sun C; Xu ZJ; Chen YW; Fan JG
    World J Gastroenterol; 2016 Nov; 22(44):9844-9852. PubMed ID: 27956809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatocellular Carcinoma in Non Alcoholic Fatty Liver Disease.
    Tovoli F; Ferri S; Piscaglia F
    Curr Pharm Des; 2020; 26(32):3909-3914. PubMed ID: 32348210
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Non-Invasive Assessment of Circulating D-Loop and mt-ccf Levels Opens an Intriguing Spyhole into Novel Approaches for the Tricky Diagnosis of NASH.
    Paolini E; Longo M; Corsini A; Dongiovanni P
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative Prediction of Steatosis in Patients with Non-Alcoholic Fatty Liver by Means of Hepatic MicroRNAs Present in Serum and Correlating with Hepatic Fat.
    Quintás G; Caiment F; Rienda I; Pérez-Rojas J; Pareja E; Castell JV; Jover R
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating microRNA‑135a‑3p in serum extracellular vesicles as a potential biological marker of non‑alcoholic fatty liver disease.
    Jiang H; Qian Y; Shen Z; Liu Y; He Y; Gao R; Shen M; Chen S; Fu Q; Yang T
    Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 33955511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum miR-29a and miR-122 as Potential Biomarkers for Non-Alcoholic Fatty Liver Disease (NAFLD).
    Jampoka K; Muangpaisarn P; Khongnomnan K; Treeprasertsuk S; Tangkijvanich P; Payungporn S
    Microrna; 2018; 7(3):215-222. PubMed ID: 29848284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.